TULKROSSI
LIVE

Serial Number

97730485

Owner

TURNING POINT THERAPEUTICS, INC.

Attorney

Marilyn F. Kelly

Filing Date

Dec 23, 2022

Add to watchlist:

No watchlists yet
View on USPTO

TULKROSSI Trademark

Serial Number: 97730485

TULKROSSI is a trademark filed by TURNING POINT THERAPEUTICS, INC. on December 23, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

TURNING POINT THERAPEUTICS, INC. (35 trademarks)

10628 SCIENCE CENTER DRIVE, SUITE 200
SAN DIEGO, CA 92121

Entity Type: 03

Trademark Details

Filing Date

December 23, 2022

Registration Date

Not Registered

Published for Opposition

May 28, 2024

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 12, 2026 EXRA
SOU EXTENSION 3 GRANTED
Jan 12, 2026 EX3G
SOU EXTENSION 3 FILED
Jan 12, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 24, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jun 24, 2025 EX2G
SOU EXTENSION 2 FILED
Jun 24, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jan 7, 2025 EX1G
SOU EXTENSION 1 FILED
Jan 7, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 7, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 23, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 28, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 28, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 8, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 24, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 14, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 14, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 23, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 23, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 23, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 23, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 29, 2022 NWOS
NEW APPLICATION ENTERED
Dec 27, 2022 NWAP